Companies / Boehringer Ingelheim
Boehringer Ingelheim
CompanyBoehringer Ingelheim is a German pharmaceutical company founded in 1885 in Ingelheim am Rhein. It is headquartered in Ingelheim and operates globally across human pharmaceuticals, animal health, and biopharmaceuticals. The company is privately held and owned by the Boehringer, Liebrecht, and von Baumbach families.
- Trials
- 2290
- Recruiting
- 49
- Completed
- 1998
- With results
- 1100
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | Active | Completed | Terminated | Withdrawn | Suspended | Approved for marketing | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | 1 | — | — | — | — | — | 1 |
| Phase 1 | 17 | 3 | 20 | 939 | 65 | 10 | 5 | — | — | 1059 |
| Phase 1/2 | 2 | 1 | 1 | 8 | 2 | — | — | — | — | 14 |
| Phase 2 | 9 | — | 6 | 236 | 36 | 7 | — | — | — | 294 |
| Phase 2/3 | — | — | — | 7 | 5 | 1 | — | — | — | 13 |
| Phase 3 | 19 | 2 | 1 | 340 | 21 | 4 | — | — | — | 387 |
| Phase 4 | — | — | — | 116 | 10 | — | — | — | — | 126 |
| Not applicable | — | — | 1 | 9 | — | 1 | — | — | — | 11 |
| Unknown | 2 | 2 | 5 | 342 | 14 | 8 | — | 8 | 4 | 385 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Pulmonary Disease, Chronic Obstructive | — | 7 | — | 33 | — | 80 | 32 | 2 | 81 | 235 |
| Diabetes Mellitus, Type 2 | — | 19 | — | 18 | — | 50 | 9 | — | 34 | 130 |
| Hypertension | — | 1 | — | 4 | — | 43 | 26 | — | 48 | 122 |
| HIV Infections | — | 12 | 2 | 12 | 1 | 12 | 7 | 1 | 20 | 67 |
| Carcinoma, Non-Small-Cell Lung | — | 21 | — | 10 | — | 14 | 3 | 1 | 17 | 66 |
| Asthma | — | 7 | — | 26 | — | 17 | 6 | — | 6 | 62 |
| Neoplasms | 1 | 55 | — | 3 | — | — | — | — | 2 | 61 |
| Atrial Fibrillation | — | — | — | 3 | — | 3 | 3 | — | 36 | 45 |
| Parkinson Disease | — | — | — | 2 | 1 | 10 | 7 | — | 22 | 42 |
| Idiopathic Pulmonary Fibrosis | — | 1 | — | 6 | — | 5 | 5 | — | 18 | 35 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Boehringer Ingelheim | 2290 | 400 |
Frequent collaborators
| # | Collaborator | Trials |
|---|---|---|
| 1 | Eli Lilly and Company | 88 |
| 2 | Pfizer | 23 |
| 3 | Bayer | 2 |
| 4 | GlaxoSmithKline | 2 |
| 5 | Uppsala University | 2 |
| 6 | Astellas Pharma Inc | 1 |
| 7 | Carelon Research | 1 |
| 8 | Chengdu Big Data Association | 1 |
| 9 | Children's Hospital Acquired Thrombosis consortium | 1 |
| 10 | China-Japan Friendship Hospital | 1 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Tiotropium Bromide | 128 |
| 2 | empagliflozin | 123 |
| 3 | Telmisartan | 118 |
| 4 | Linagliptin | 89 |
| 5 | nintedanib | 86 |
| 6 | Afatinib | 80 |
| 7 | Dabigatran | 79 |
| 8 | olodaterol | 61 |
| 9 | Ritonavir | 56 |
| 10 | Metformin | 48 |
Evidence
- Results reported
- 55.1%1100 of 1998 completed
- Published
- 0.1%1 of 1998 completed
- Primary endpoint met
- 60.8%1058 of 1739 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 71
- Median duration
- 14.6months
- Countries
- 81
- Study sites
- 58251
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 146
- Phase 1
- 32
- Phase 1/2
- 49
- Phase 2
- 104
- Phase 2/3
- 112
- Phase 3
- 400
- Phase 4
- 223
- Not applicable
- 53
- Unknown
- 1464
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Berlin | Germany | 291 |
| 2 | Barcelona | Spain | 246 |
| 3 | Madrid | Spain | 227 |
| 4 | Seoul | South Korea | 195 |
| 5 | Houston | United States | 193 |
| 6 | Paris | France | 166 |
| 7 | Toronto | Canada | 165 |
| 8 | London | United Kingdom | 164 |
| 9 | Biberach | Germany | 153 |
| 10 | Hamburg | Germany | 150 |
Terminations
- Terminated
- 153
- Withdrawn
- 31
- Suspended
- 5
- Stopped for recruitment
- 0.4%10 of 2290 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT07395258 Suspended | Suspended | Temporary enrolment hold as a precautionary measure following a safety event in a related trial | 2032-02-12 |
| NCT06886009 Withdrawn | Withdrawn | Sponsor decision | 2029-06-08 |
| NCT07176975 Suspended | Suspended | company decision | 2029-05-22 |
| NCT05155332 Suspended | Suspended | Sponsor decision - temporary enrolment hold as a precautionary measure following a safety event. | 2028-10-31 |
| NCT06370871 Withdrawn | Withdrawn | Sponsor decision. | 2028-10-13 |
| NCT07656792 Suspended | Suspended | Sponsor decision - hold following the evaluation of a safety event. No current sites in the US. | 2026-11-26 |
| NCT06916702 Suspended | Suspended | Sponsor decision - hold following the evaluation of a safety event. No current sites in the US. | 2026-10-13 |
| NCT05676112 Withdrawn | Withdrawn | Company decision | 2026-09-30 |
| NCT06628622 Terminated | Terminated | Sponsor decision | 2026-07-16 |
| NCT05503030 Terminated | Terminated | Company decision | 2026-05-13 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Boehringer Ingelheim trials on ClinicalTrials.gov →